首页> 外文期刊>British Journal of Clinical Pharmacology >Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.
【24h】

Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.

机译:二氢麦角胺:动脉,小动脉和药代动力学数据之间的差异。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: To investigate the peripheral vascular effects and pharmacokinetics of dihydroergotamine (DHE) 0.5 mg after a single subcutaneous administration in humans. METHODS: A double-blind, placebo-controlled cross-over study was performed in 10 healthy male subjects. A wash-out period of 2 weeks separated the two study periods. During each period, just before and at regular intervals after drug administration, vascular measurements were performed and venous blood samples were drawn. Vessel wall properties were assessed at the brachial artery, by ultrasound and applanation tonometry. Blood pressure and heart rate were recorded with an oscillometric device. Forearm blood flow was measured with venous occlusion plethysmography. For all parameter-time curves the area under the curve (AUC) was calculated. Differences in AUC after placebo and DHE (DeltaAUC) were analysed and the time-course of the difference assessed. DHE pharmacokinetics were analysed according to a two-compartment open model with an absorption phase. RESULTS: AUC for blood pressure, heart rate and forearm vascular resistance did not change after DHE. Brachial artery diameter and compliance decreased (P < 0.01); DeltaAUC (95% confidence interval) equalled -8.81 mm h (-12.97/-4.65) and -0.98 mm2 kPa(-1) h (-1.61/-0.34), respectively. Diameter decreased (P < 0.05) from 1 until 24 h after DHE (peak decrease 9.7% at 10 h); compliance from 2 until 32 h (24.8% at 2 h). Time to reach maximum plasma concentration of DHE averaged 0.33 +/- 0.08 h (+/- s.e.mean); terminal half-life was 5.63 +/- 1.15 h. CONCLUSIONS: DHE decreased diameter and compliance of the brachial artery whereas forearm vascular resistance remained unchanged. Thus, DHE acts on conduit arteries without affecting resistance arteries. Furthermore, a discrepancy was demonstrated between the plasma concentrations of DHE which rapidly reach peak levels and quickly decline, and its long lasting vasoconstrictor activity.
机译:目的:研究人皮下单次给药后0.5 mg二氢麦角胺(DHE)的外周血管作用和药代动力学。方法:在10名健康男性受试者中进行了一项双盲,安慰剂对照的交叉研究。 2周的淘汰期将两个研究期分开。在每个时期内,在给药前和给药后定期进行血管测量并抽取静脉血样本。通过超声和​​压平眼压计评估肱动脉的血管壁性质。用示波法记录血压和心率。用静脉阻塞体积描记法测量前臂血流量。对于所有参数时间曲线,计算曲线下的面积(AUC)。分析安慰剂和DHE(DeltaAUC)后的AUC差异,并评估差异的时程。根据具有吸收阶段的两室开放模型分析DHE药代动力学。结果:DHE后血压,心率和前臂血管阻力的AUC没有变化。肱动脉直径和顺应性降低(P <0.01); DeltaAUC(95%置信区间)分别等于-8.81 mmh(-12.97 / -4.65)和-0.98 mm2 kPa(-1)h(-1.61 / -0.34)。在DHE后1到24小时,直径减小(P <0.05)(10小时峰值降低9.7%);从2到32小时(2小时时为24.8%)的顺应性。达到DHE最大血浆浓度的时间平均为0.33 +/- 0.08 h(+/- s.e.mean);终末半衰期为5.63 +/- 1.15小时。结论:DHE减小了肱动脉的直径和顺应性,而前臂血管阻力保持不变。因此,DHE作用于导管动脉而不影响阻力动脉。此外,在快速达到峰值水平并迅速下降的DHE血浆浓度与其持久的血管收缩活性之间显示出差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号